Zydus Lifesciences Share Price in Focus After USFDA Approves Menopause Treatment

Zydus Lifesciences announced on October 21, 2026, that the US Food and Drug Administration had approved its generic version of the Estradiol and Levonorgestrel Transdermal System. 

Approval Comes with Potential 180-Day Exclusivity 

The product has been designated a Competitive Generic Therapy (CGT) by the USFDA. It may qualify for 180 days of exclusivity under the CGT pathway, subject to US regulatory requirements. Any applicable exclusivity period would begin when the product is first commercially marketed. 

Product to Be Made in Gujarat 

The treatment is used to manage moderate to severe menopause symptoms and may also help prevent osteoporosis in postmenopausal women. Zydus will manufacture the product at its Moraiya facility near Ahmedabad, Gujarat. 

The product had annual US sales of approximately $45.7 million as of August 2026, according to IQVIA data cited by the company. As of September 30, 2026, Zydus had received 458 approvals and filed 516 abbreviated new drug applications (ANDAs) with the USFDA. 

Read More: Hexaware Technologies Share Price in Focus; Board Declares ₹9.50 Dividend Per Share! 

Zydus Lifesciences Share Price Performance 

As of October 21, 2026, at 12:26 PM, Zydus Lifesciences share price was trading at ₹1,107.80 per share, reflecting a 0.55% change from the previous trading session. 

Conclusion 

The USFDA approval adds another product to Zydus Lifesciences' US generics portfolio. The potential 180-day exclusivity could give the company a period of limited generic competition, subject to the applicable conditions. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.